InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by Alspaugh Jonathan, Chief Financial Officer. Insider active across 1 companies, notably Aeglea BioTherapeutics, Inc.. Aggregated, 5 reports have been published. Total volume traded: €575k. The latest transaction was disclosed on 11 March 2022 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations5 total
€141,63975,000 shares@ €1.888524.6% of flow
Common Stock
SEC:0001209191-22-018941:0·
Ideal exit: 6 Dec 2022 (T+270)
€163,94050,000 shares@ €3.278875.6% of flow
Common Stock
SEC:0001209191-21-069349·
Ideal exit: 5 Sept 2022 (T+270)
€163,94050,000 shares@ €3.278828.5% of flow
Common Stock
SEC:0001209191-21-069349:0·
Ideal exit: 5 Sept 2022 (T+270)
€52,8659,780 shares@ €5.405524.4% of flow
Common Stock
SEC:0001209191-21-052272·
Ideal exit: 13 May 2022 (T+270)
€52,8659,780 shares@ €5.40559.2% of flow
Common Stock
SEC:0001209191-21-052272:0·
Ideal exit: 13 May 2022 (T+270)
5 of 5 declarations
About Alspaugh Jonathan
Jonathan Alspaugh is the Chief Financial Officer of Aeglea BioTherapeutics, Inc. He is responsible for the company's financial management, including budgeting and performance analysis. His role is essential in ensuring the financial viability of the organization.
